Why the study?
Accurate standardization of left atrium volume in patients with obesity is challenging, prompting evaluation of indexing to height2 versus body surface area and its relation to left atrial function.
Does indexing left atrial volume to height² improve the identification of left atrial dysfunction compared to indexing to BSA in patients with moderate to severe obesity?
Does indexing left atrial volume to height² improve the identification of left atrial dysfunction compared to indexing to BSA in patients with moderate to severe obesity?
Indexing left atrial volume to height² rather than body surface area improves the identification of left atrial dysfunction in patients with moderate to severe obesity.
LAEh2 may detect more LA dysfunction than BSA indexing in obese patients; hypothesis-generating and should not yet change practice.
Accurate standardization of left atrium volume (LAV) in patients with obesity is challenging. The aim of this study was to investigate and to examine the relation between LAV indexed to height² and left atrial function in patients with moderate to severe obesity. Echocardiograms of patients with moderate to severe obesity (body mass index (BMI) ≥ 35 kg/m²) without known cardiac disease were analyzed. LAV was indexed to body surface area (BSA) and height², and patients were divided into those with or without left atrial enlargement (LAE) based on normalization using either BSA (LAEbsa) or height² (LAEh2). Using speckle tracking echocardiography, LA reservoir strain (LASr), LA conduit strain (LAScd), and LA contractile strain (LASct) were assessed as a measure of LA function. LA dysfunction was defined as LASct < 14%. A total of 142 patients were included in the analysis of whom 54.2% had LAEh2 and 18.3% LAEBSA. The LAEh2 group had significantly lower LASct (12.2% ± 3.2% vs. 13.6% ± 4.5%, p = 0.019) as compared to the patients without LAEh2. Significantly more patients with LA dysfunction would be correctly identified by LAEh2 than by LAEBSA (41.5% vs. 15.0%, p < 0.001). In patients with moderate to severe obesity, the use of LAEh2 identified significantly more patients with decreased LA function. LAVh2 should be preferred over LAVBSA in patients with moderate to severe obesity.
No takes yet. Share an insight, caveat, or question.
Aga et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: